334 related articles for article (PubMed ID: 9891532)
1. TATI (tumor associated trypsin inhibitor) and cancer antigen 125 (CA 125) in patients with early-stage endometrial cancer.
Peters-Engl C; Buxbaum P; Ogris E; Sevelda P; Medl M
Anticancer Res; 1998; 18(6B):4635-9. PubMed ID: 9891532
[TBL] [Abstract][Full Text] [Related]
2. Tumor-associated trypsin inhibitor (TATI) and cancer antigen 125 (CA125) in patients with epithelial ovarian cancer.
Peters-Engl C; Medl M; Ogris E; Leodolter S
Anticancer Res; 1995; 15(6B):2727-30. PubMed ID: 8669854
[TBL] [Abstract][Full Text] [Related]
3. Preoperative serum CA-125 levels in treating endometrial cancer.
Powell JL; Hill KA; Shiro BC; Diehl SJ; Gajewski WH
J Reprod Med; 2005 Aug; 50(8):585-90. PubMed ID: 16220763
[TBL] [Abstract][Full Text] [Related]
4. Evaluation of urine tumor-associated trypsin inhibitor, CYFRA 21-1, and urinary bladder cancer antigen for detection of high-grade bladder carcinoma.
Gkialas I; Papadopoulos G; Iordanidou L; Stathouros G; Tzavara C; Gregorakis A; Lykourinas M
Urology; 2008 Nov; 72(5):1159-63. PubMed ID: 18514770
[TBL] [Abstract][Full Text] [Related]
5. Tumour-associated trypsin inhibitor (TATI) in patients with colorectal cancer: a comparison with CEA, CA 50 and CA 242.
Pasanen P; Eskelinen M; Kulju A; Penttilä I; Janatuinen E; Alhava E
Scand J Clin Lab Invest; 1995 Apr; 55(2):119-24. PubMed ID: 7667604
[TBL] [Abstract][Full Text] [Related]
6. Predictive power of sexual hormones and tumor markers in endometrial cancer.
Kanat-Pektas M; Yenicesu O; Gungor T; Bilge U
Arch Gynecol Obstet; 2010 Apr; 281(4):709-15. PubMed ID: 19777250
[TBL] [Abstract][Full Text] [Related]
7. TATI (tumour-associated trypsin inhibitor) as a marker of ovarian cancer.
Medl M; Ogris E; Peters-Engl C; Leodolter S
Br J Cancer; 1995 May; 71(5):1051-4. PubMed ID: 7734298
[TBL] [Abstract][Full Text] [Related]
8. Use of preoperative serum CA-125 levels for prediction of lymph node metastasis and prognosis in endometrial cancer.
Chung HH; Kim JW; Park NH; Song YS; Kang SB; Lee HP
Acta Obstet Gynecol Scand; 2006; 85(12):1501-5. PubMed ID: 17260229
[TBL] [Abstract][Full Text] [Related]
9. [The plasma levels and diagnostic utility of stem cell factor in patients with endometrial cancer and myoma uteri].
Ławicki S; Bedkowska GE; Gacuta-Szumarska E; Czygier M; Szmitkowski M
Pol Merkur Lekarski; 2009 Jun; 26(156):609-15. PubMed ID: 19711726
[TBL] [Abstract][Full Text] [Related]
10. Urinary levels of tumor-associated trypsin inhibitor (TATI) in the detection of transitional cell carcinoma of the urinary bladder.
Shariat SF; Herman MP; Casella R; Lotan Y; Karam JA; Stenman UH
Eur Urol; 2005 Sep; 48(3):424-31. PubMed ID: 15963628
[TBL] [Abstract][Full Text] [Related]
11. Significance of a single CA 125 assay combined with ultrasound in the early detection of ovarian and endometrial cancer.
Vuento MH; Stenman UH; Pirhonen JP; Mäkinen JI; Laippala PJ; Salmi TA
Gynecol Oncol; 1997 Jan; 64(1):141-6. PubMed ID: 8995563
[TBL] [Abstract][Full Text] [Related]
12. Serum tetranectin and CA125 in endometrial adenocarcinoma.
Lundstrøm MS; Høgdall CK; Nielsen AL; Nyholm HC
Anticancer Res; 2000; 20(5C):3903-6. PubMed ID: 11268474
[TBL] [Abstract][Full Text] [Related]
13. [Clinical value of combined detection of serum human epididymal secretory protein E4 and CA(125) in the diagnosis of endometrial carcinoma].
Zhang AM; Zhang P
Zhonghua Fu Chan Ke Za Zhi; 2012 Feb; 47(2):125-8. PubMed ID: 22455745
[TBL] [Abstract][Full Text] [Related]
14. Preoperative serum CA 125 level in the prediction of the stage of disease in endometrial carcinoma.
Yildiz A; Yetimalar H; Kasap B; Aydin C; Tatar S; Soylu F; Yildiz FS
Eur J Obstet Gynecol Reprod Biol; 2012 Oct; 164(2):191-5. PubMed ID: 22727919
[TBL] [Abstract][Full Text] [Related]
15. Validation of serum biomarkers for detection of early- and late-stage endometrial cancer.
Farias-Eisner G; Su F; Robbins T; Kotlerman J; Reddy S; Farias-Eisner R
Am J Obstet Gynecol; 2010 Jan; 202(1):73.e1-5. PubMed ID: 19766980
[TBL] [Abstract][Full Text] [Related]
16. Soluble urokinase plasminogen activator receptor in preoperatively obtained plasma from patients with gynecological cancer or benign gynecological diseases.
Riisbro R; Stephens RW; Brünner N; Christensen IJ; Nielsen HJ; Heilmann L; von Tempelhoff GF
Gynecol Oncol; 2001 Sep; 82(3):523-31. PubMed ID: 11520150
[TBL] [Abstract][Full Text] [Related]
17. Squamous cell carcinoma antigen, tumor associated trypsin inhibitor and tissue polypeptide specific antigen in follow up of stage III cervical cancer.
Gitsch G; Kainz C; Joura E; Fröhlich B; Bieglmayr C; Tatra G
Anticancer Res; 1992; 12(4):1247-9. PubMed ID: 1503417
[TBL] [Abstract][Full Text] [Related]
18. Serum CA 125 measurements to identify patients with endometrial cancer who require lymphadenectomy.
Koper NP; Massuger LF; Thomas CM; Kiemeney LA; Verbeek AL
Anticancer Res; 1998; 18(3B):1897-902. PubMed ID: 9677441
[TBL] [Abstract][Full Text] [Related]
19. Serum levels of the tumour-associated trypsin inhibitor in patients with endometriosis.
Medl M; Ogris E; Peters-Engl C; Mierau M; Buxbaum P; Leodolter S
Br J Obstet Gynaecol; 1997 Jan; 104(1):78-81. PubMed ID: 8988701
[TBL] [Abstract][Full Text] [Related]
20. Significance of the tumour markers CA 125 II, CA 72-4, CASA and CYFRA 21-1 in ovarian carcinoma.
Hasholzner U; Baumgartner L; Stieber P; Meier W; Hofmann K; Fateh-Moghadam A
Anticancer Res; 1994; 14(6B):2743-6. PubMed ID: 7532929
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
